INTERNATIONAL JOURNAL OF
PHARMACEUTICAL AND HEALTHCARE INNOVATION
journal homepage: www.ijphi.com

OPEN ACCESS

Review Article

Targeting Alpha-Synuclein as a Treatment for Parkinson's Disease

Ramdas Bhat[1]*, Maziya[2]

[1]Associate Professor, Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Frangipete Post, Mangalore, Karnataka, India. 5741432

[2] UG scholar, Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Frangipete Post, Mangalore, Karnataka, India. 574143

Article Info

Article history:

Manuscript ID:

IJPHI2605132024

Received: 26- July -2024

Revised :5-August-2024

Accepted: 13-August-2024

Available online: July 2024

Keywords:
Alpha-synuclein, Neurodegeneration, Disease-modifying therapies, Lewy bodies, Personalized medicine.

Corresponding Author:
ramdas21@gmail.com

Abstract

Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to motor symptoms such as tremor, rigidity, and bradykinesia. Beyond these motor manifestations, Parkinson's disease encompasses non-motor symptoms, including cognitive impairment and autonomic dysfunction, significantly impacting patients' quality of life. Current treatments primarily focus on dopamine replacement, emphasizing the need for disease-modifying therapies. A key pathological feature of Parkinson's disease is the accumulation of misfolded alpha-synuclein, forming Lewy bodies and contributing to neurodegeneration through various mechanisms. Recent research highlights alpha-synuclein as a promising target for novel therapies aimed at reducing its production, enhancing clearance, preventing aggregation, and blocking cell-to-cell propagation. This review examines strategies under investigation, including genetic approaches, immunotherapies, and small molecule inhibitors. Despite advancements, challenges remain, such as overcoming the blood-brain barrier and addressing disease heterogeneity. We discuss these limitations and explore future directions focused on advanced drug delivery systems, personalized medicine, and combination therapies. Ongoing clinical trials continue to explore the efficacy and safety of these innovative approaches, offering hope for transformative advances in Parkinson's disease treatment. This article highlights the importance of collaborative efforts between researchers and clinicians in translating findings into effective clinical interventions. By comprehensively examining the potential and challenges of targeting alpha-synuclein, we aim to provide insights into the future of Parkinson's disease treatment and its potential to significantly improve patients' lives.

INTRODUCTION

Parkinson's disease (PD) is a complex and progressive neurodegenerative disorder that affects millions of people worldwide, with a prevalence of 1-2% in individuals over the age of 65 [1]. Characterized primarily by the loss of dopaminergic neurons in the substantia nigra pars compacta, PD manifests through a triad of cardinal motor symptoms: resting tremor, rigidity, and bradykinesia [2]. However, the impact of PD extends far beyond these motor manifestations, encompassing a wide range of non-motor symptoms that can often precede the onset of motor symptoms by years or even decades. These non-motor symptoms include cognitive impairment, depression, anxiety, sleep disorders, olfactory deficits, and autonomic dysfunction affecting blood pressure, digestion, and urinary function. The combination of motor and non-motor symptoms significantly impacts patients' quality of life and poses substantial challenges to caregivers and healthcare systems [4]. Current treatment strategies for PD primarily focus on managing symptoms through dopamine replacement therapy, most commonly with levodopa. While effective in alleviating motor symptoms, especially in the early stages of the disease, these treatments do not address the underlying disease process and are associated with long-term complications such as motor fluctuations and dyskinesias. This limitation underscores the urgent need for disease-modifying therapies that can slow, halt, or potentially reverse the progression of PD, driving researchers to explore the fundamental pathophysiology of the disease in search of novel therapeutic targets [5].

In recent years, alpha-synuclein has emerged as one of the most promising targets for PD treatment. This small, soluble protein is abundantly expressed in the brain, particularly in presynaptic terminals, where it plays a role in synaptic

function and vesicle trafficking under normal conditions [6]. However, in PD and other related disorders collectively known as synucleinopathies, alpha-synuclein misfolds and aggregates, forming insoluble fibrils that accumulate in neurons as Lewy bodies and Lewy neurites – hallmark pathological features of the disease. The accumulation of misfolded alpha-synuclein is believed to contribute to neurodegeneration through multiple mechanisms, including disruption of cellular homeostasis, mitochondrial dysfunction, oxidative stress, impaired protein degradation, neuroinflammation, and synaptic dysfunction . Moreover, recent evidence suggests that misfolded alpha-synuclein can spread from cell to cell in a prion-like manner, potentially explaining the progressive nature of PD and its characteristic pattern of spread through the brain [7]. Given its pivotal role in PD pathogenesis, alpha-synuclein has become a primary target for potential disease-modifying therapies. Researchers are exploring various approaches to target this protein, including reducing alpha-synuclein production, enhancing its clearance, preventing its aggregation, and blocking its propagation. These strategies aim to interrupt the pathological cascade initiated by alpha-synuclein, potentially slowing or halting disease progression. This article delves into the intricate relationship between alpha-synuclein and Parkinson's disease, exploring the protein's normal function, its role in PD pathogenesis, and the various therapeutic approaches being developed to target it. We will examine the promising avenues of research, the challenges faced in developing these therapies, and the potential impact these treatments could have on the lives of millions affected by PD. As we stand on the cusp of potentially transformative advances in PD treatment, understanding the role of alpha-synuclein and the strategies to target it becomes crucial not only for developing more effective treatments but also for

gaining insights into the fundamental mechanisms of neurodegeneration.

PATHOLOGY OF ALPHA-SYNUCLEIN IN PARKINSON'S DISEASE:

Parkinson's disease (PD) relentlessly progresses due to the demise of dopaminergic neurons and the accumulation of Lewy bodies (LBs) and Lewy neurites (LNs) within the brain. α-Alpha-synuclein, a small protein abundantly expressed in the brain, plays a central role in the pathology of Parkinson's disease (PD). Under normal conditions, alpha-synuclein is involved in synaptic function and neurotransmitter release. However, in PD, it undergoes a conformational change, misfolding from its native state into beta-sheet-rich structures. This misfolding leads to the formation of various aggregated species, including oligomers, protofibrils, and fibrils. The accumulation of these aggregates results in the formation of Lewy bodies and Lewy neurites, hallmark pathological features of PD. The exact trigger for this misfolding and aggregation is not fully understood, but factors such as genetic mutations, post-translational modifications, oxidative stress, and impaired protein degradation have been implicated [8,9].

The accumulation of misfolded and aggregated alpha-synuclein contributes to neurodegeneration through several mechanisms. These include mitochondrial dysfunction, synaptic impairment, disruption of protein degradation pathways, neuroinflammation, and axonal transport deficits. Recent evidence also suggests that misfolded alpha-synuclein can spread from cell to cell in a prion-like manner, potentially explaining the progressive nature of PD and its characteristic pattern of spread through the brain. This spatiotemporal progression of alpha-synuclein pathology correlates closely with the clinical progression of PD, from early non-motor symptoms to later cognitive decline. The complex pathology of alpha-synuclein in Parkinson's disease

underscores its central role in the disease process and highlights its potential as a therapeutic target. By addressing various aspects of alpha-synuclein pathology – from preventing misfolding and aggregation to enhancing clearance and blocking propagation – researchers aim to develop disease-modifying therapies that can slow or halt the progression of this devastating neurodegenerative disorder [9,10].

THERAPEUTIC APPROACH FOR TARGETING ALPHA-SYNUCLEIN IN PARKINSON'S DISEASE:

The central role of alpha-synuclein in Parkinson's disease (PD) pathogenesis has made it a prime target for therapeutic intervention. Researchers are exploring multiple strategies to address the toxic effects of alpha-synuclein aggregation and propagation. One major approach focuses on reducing alpha-synuclein levels in the brain. This includes techniques such as RNA interference (RNAi) and antisense oligonucleotides (ASOs) to decrease alpha-synuclein production at the genetic level. Another strategy involves enhancing the clearance of alpha-synuclein aggregates. This can be achieved through the upregulation of autophagy and the ubiquitin-proteasome system, the body's natural protein degradation pathways. Additionally, immunotherapy approaches, using both active vaccination to stimulate the immune system and passive immunization with pre-made antibodies, are being developed to target and clear pathological forms of alpha-synuclein [11,12].

A second set of therapeutic strategies aims to prevent alpha-synuclein aggregation and propagation. Small molecule inhibitors that can bind to alpha-synuclein and prevent its misfolding or aggregation are under investigation. These compounds work by stabilizing the native form of the protein or by preventing the formation of toxic oligomers. Another promising approach involves targeting the cell-to-cell transmission of misfolded alpha-synuclein.

This includes developing compounds that can block the release of alpha-synuclein from neurons or prevent its uptake by neighboring cells. Furthermore, researchers are exploring ways to enhance the activity of molecular chaperones, proteins that assist in proper protein folding and can help maintain alpha-synuclein in its non-toxic form. Each of these approaches presents unique challenges and opportunities, and it's likely that a combination of strategies may be necessary to effectively combat the complex pathology of PD. As these therapeutic approaches progress through preclinical and clinical trials, they offer hope for the development of disease-modifying treatments that could significantly impact the lives of individuals affected by Parkinson's disease [13,14].



Figure 1 Formation of Lewy body from Alpha-Synuclein



Figure 2 Pathway of degradation of Alpha-Synuclein



Figure 3 Therapeutic Approach For Targeting Alpha-Synuclein In Parkinson's Disease.

LIMITATIONS OF TARGETING ALPHA-SYNUCLEIN IN PARKINSON'S DISEASE

While targeting alpha-synuclein holds promise as a therapeutic strategy for Parkinson's disease (PD), several significant limitations and challenges need to be addressed. One major obstacle is the blood-brain barrier (BBB), which restricts the entry of many potential therapeutics into the central nervous system. This limitation is particularly relevant for large molecules like antibodies used in immunotherapy approaches. Additionally, the widespread distribution of alpha-synuclein throughout the brain makes it challenging to achieve sufficient therapeutic concentrations in all affected areas. Another critical concern is the potential side effects of reducing alpha-synuclein levels. Given its normal physiological functions in synaptic transmission and vesicle trafficking, a dramatic reduction in alpha-synuclein could lead to unintended consequences on neuronal function. Furthermore, the timing

of intervention is crucial; by the time motor symptoms appear and PD is diagnosed, significant neurodegeneration has often already occurred, potentially limiting the effectiveness of alpha-synuclein-targeted therapies [15-17].

The heterogeneity of PD presents another significant challenge. Not all cases of PD may be primarily driven by alpha-synuclein pathology, and the disease can vary considerably in its clinical presentation and progression among patients. This variability makes it difficult to design one-size-fits-all treatments and necessitates the development of personalized therapeutic approaches. Moreover, alpha-synuclein pathology in PD often coexists with other protein aggregates and cellular dysfunctions, suggesting that targeting alpha-synuclein alone may not be sufficient to halt disease progression in all cases. There are also technical challenges in developing reliable biomarkers to monitor alpha-synuclein pathology and treatment efficacy in living patients, which is crucial for clinical trials and personalized treatment strategies. Lastly, the potential for long-term side effects of chronic alpha-synuclein-targeted therapies remains largely unknown, necessitating careful long-term follow-up studies. Despite these limitations, the central role of alpha-synuclein in PD pathogenesis continues to make it an attractive therapeutic target, and ongoing research is actively working to overcome these challenges [8,18,19].

FUTURE DIRECTIONS

The future of alpha-synuclein-targeted therapies for Parkinson's disease (PD) is poised for significant advancements. One promising direction is the development of more sophisticated drug delivery systems to overcome the blood-brain barrier challenge. This includes the exploration of nanoparticle-based delivery methods and the use of viral vectors for gene therapy approaches. Additionally, researchers are focusing on developing small molecules that can selectively target pathological forms of alpha-synuclein while sparing its

normal physiological functions. This approach could minimize potential side effects associated with broad alpha-synuclein reduction. Another exciting avenue is the advancement of immunotherapy strategies, with ongoing clinical trials evaluating both active and passive immunization approaches. Future research will likely focus on optimizing these immunotherapies to enhance their specificity and efficacy. Moreover, the field is moving towards combination therapies that target multiple aspects of PD pathology simultaneously, recognizing the complex nature of the disease.

Parallel to therapeutic development, significant effort is being directed towards improving early diagnosis and monitoring of PD progression. This includes the development of more sensitive and specific biomarkers for alpha-synuclein pathology, potentially utilizing advanced neuroimaging techniques or assays of biological fluids. Such biomarkers would not only aid in earlier diagnosis but also facilitate the evaluation of treatment efficacy in clinical trials. Another important future direction is the pursuit of personalized medicine approaches in PD treatment. This involves stratifying patients based on genetic profiles, biomarkers, and clinical presentations to tailor alpha-synuclein-targeted therapies more effectively. Furthermore, emerging technologies such as artificial intelligence and machine learning are expected to play increasing roles in drug discovery, patient stratification, and treatment optimization. Lastly, as our understanding of the basic biology of alpha-synuclein continues to grow, new therapeutic targets and approaches are likely to emerge, potentially revolutionizing our approach to treating PD and other synucleinopathies.

CLINICAL TRIALS FOR PARKINSON'S DISEASE INTERVENTIONS

Trial	Phase	Description	Estimated Completion Year	Reference
SPARK (Cinpanemab)	Phase not provided	Evaluating monoclonal antibody targeting aggregated alpha-synuclein	-	20
PASADENA (Prasinezumab)	Phase not provided	Evaluating monoclonal antibody targeting aggregated alpha-synuclein	-	20
Anle138b	Phase not provided	Small molecule targeting alpha-synuclein aggregation	-	21
NPT200-11	Phase not provided	Small molecule targeting alpha-synuclein aggregation	-	22
BRT-DA01 (BlueRock Therapeutics)	Phase 1	Evaluating safety and tolerability of pluripotent stem cell-derived dopaminergic neurons	2023	23
SPARX3	Phase 3	Investigating high-intensity treadmill exercise for slowing Parkinson's disease progression	2025	24
Cleveland Clinic Pragmatic Cyclical Lower Extremity Exercise Trial	Phase 2	Examining high-intensity aerobic exercise intervention for Parkinson's disease	2024	25

CONCLUSION

Targeting alpha-synuclein represents a promising avenue for Parkinson's disease (PD) treatment, supported by extensive research and alignment with existing literature. While challenges such as blood-brain barrier permeability and specificity of therapeutic agents persist, ongoing clinical trials offer hope for breakthroughs in PD management. Personalized medicine approaches and combination therapies show potential for enhancing treatment efficacy and minimizing side effects. Continued collaboration between researchers and clinicians is crucial for translating preclinical findings into clinically meaningful interventions,

ultimately improving outcomes for individuals living with PD.

Conflict of Interest: None.

Financial support: None.

Ethical statement: None.

REFERENCE

1. Brakedal B, Toker L, Haugarvoll K, Tzoulis C. A nationwide study of the incidence, prevalence and mortality of Parkinson's disease in the Norwegian population. npj Parkinsons Dis. 2022;8(1):19.
2. Sharma R. Parkinson disease. Radiopaedia.org [Internet]. 2024 Jul 15 [cited 2024 Jun 12]; Available from: https://radiopaedia.org/articles/parkinson-disease-1
3. Petersen MV. Non-motor symptoms in Parkinson's disease: Nature and burden [Internet]. Neurotorium. 2022 [cited 2024 Jun 12]. Available from: https://neurotorium.org/non-motor-symptoms-in-parkinsons-disease-nature-and-burden/
4. Zahoor I, Shafi A, Haq E. Pharmacological treatment of Parkinson's disease. Exon Publ. 2018:129-44.
5. Sharma M, Burré J. α-Synuclein in synaptic function and dysfunction. Trends Neurosci. 2023;46(2):153-66.
6. Wiseman JA, Murray HC, Faull RLMF, Dragunow M, Turner CP, Dieriks BV, et al. Aggregate-prone brain regions in Parkinson's disease are rich in unique N-terminus α-synuclein conformers with high proteolysis susceptibility. npj Parkinsons Dis. 2024;10(1):1-18.
7. Bigi A, Cascella R, Cecchi C. α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies. Neural Regen Res. 2023;18(11):2332-42.
8. Gómez-Benito M, Granado N, García-Sanz P, Michel A, Dumoulin M, Moratalla R. Modeling Parkinson's disease with the alpha-synuclein protein. Front Pharmacol. 2020;11:356.
9. Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM. Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. F1000Res. 2017;6:1604.
10. Jan A, Gonçalves NP, Vaegter CB, Jensen PH, Ferreira N. The prion-like spreading of alpha-synuclein in Parkinson's disease: update on models and hypotheses. Int J Mol Sci. 2021;22(15):8338.
11. Vargas JY, Grudina C, Zurzolo C. The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease. Ageing Res Rev. 2019;50:89-101.
12. Saramowicz K, Siwecka N, Galita G, Kucharska-Lusina A, Rozpędek-Kamińska W, Majsterek I. Alpha-synuclein contribution to neuronal and glial damage in Parkinson's disease. Int J Mol Sci. 2023;25(1):360.
13. Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting alpha-synuclein as a therapy for Parkinson's disease. Front Mol Neurosci. 2019;12:299.
14. Jasutkar HG, Oh SE, Mouradian MM. Therapeutics in the pipeline targeting α-synuclein for Parkinson's disease. Pharmacol Rev. 2022;74(1):207-37.
15. Stoker TB, Barker RA. Recent developments in the treatment of Parkinson's Disease. F1000Res. 2020;9:862.
16. Henriquez G, Narayan M. Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson's disease. Explor Neuroprot Ther. 2023;3(4):207-34.
17. Magalhães P, Lashuel HA. Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other

synucleinopathies. npj Parkinsons Dis. 2022;8(1):93.
18. Wüllner U, Borghammer P, Choe C, Csoti I, Falkenburger B, Gasser T, et al. The heterogeneity of Parkinson's disease. J Neural Transm. 2023;130(6):827–38.
19. Hähnel T, Raschka T, Sapienza S, Klucken J, Glaab E, Corvol JC, Falkenburger BH, Fröhlich H. Progression subtypes in Parkinson's disease identified by a data-driven multi cohort analysis. npj Parkinsons Dis. 2024;10(1):95.
20. Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nat Med. 2024;30(4):1096–103.
21. Dervişoğlu R, Antonschmidt L, Nimerovsky E, Sant V, Kim M, Ryazanov S, et al. Anle138b interaction in α-synuclein aggregates by dynamic nuclear polarization NMR. Methods. 2023;214:18-27.
22. Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Sci Rep. 2018;8(1):16165.
23. Meglio M. Stem Cell Therapy BRT-DA01 Demonstrates Positive Safety, Feasibility in Early-Stage Study of Parkinson's Disease. Neurology live [Internet]. 2023 Jul 5 [cited 2024 Jul 26]; Available from: https://www.neurologylive.com/view/stem-cell-therapy-brt-da01-demonstrates-positive-safety-feasibility-early-stage-study-parkinson-disease
24. Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, et al. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022;23(1):855.
25. Schootemeijer S, Darweesh SK, de Vries NM. Clinical Trial Highlights–Aerobic Exercise for Parkinson's Disease. J Parkinsons Dis. 2022;12(8):2297-306.